Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXN | P10599 | 1/20 | 0.45 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | ADK | P55263 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | MYC | P01106 | 1/20 | 0.32 |
| ▸ | CTSZ | Q9UBR2 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | BRAF | P15056 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3503342 | 0.82 | TXN (0.55) | TXNTXNRD1ALDH1A1SMN1; SMN2FDPS | |
| SCHEMBL29390747 | 0.79 | TXN (0.34) | TXNTXNRD1ALDH1A1SMN1; SMN2FDPS | |
| SCHEMBL5032699 | 0.79 | MTOR (0.45) | TXNTXNRD1FDPSNISCHMTOR | |
| SCHEMBL317286 | 0.78 | — | — | |
| SCHEMBL29111458 | 0.78 | — | — | |
| SCHEMBL25570 | 0.78 | — | — | |
| SCHEMBL7807377 | 0.78 | — | — | |
| SCHEMBL7658749 | 0.78 | — | — | |
| SCHEMBL1145987 | 0.78 | — | — | |
| SCHEMBL8874 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1742635-B1 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF | ACEA BIOSCIENCES INC (US) | 2018-03-07 | — | — | EP | claimed |
| EP-2389358-B1 | SYNTHETIC PROCESS FOR ANTICANCER DRUG FLUORAPACIN AND TRISULFIDE DERIVATIVES | ACEA BIOSCIENCES INC (US) | 2015-09-16 | — | — | EP | claimed |
| US-8334316-B2 | Substituted organosulfur compounds and methods of using thereof | ACEA BIOSCIENCES, INC. (US) | 2012-12-18 | — | — | US | claimed |
| EP-2389358-A1 | SYNTHETIC PROCESS FOR ANTICANCER DRUG FLUORAPACIN AND TRISULFIDE DERIVATIVES | Acea Biosciences, Inc. (US) | 2011-11-30 | — | — | EP | claimed |
| US-7851657-B2 | Synthetic process for anticancer drug fluorapacin and trisulfide derivatives | ACEA BIOSCIENCES, INC. (US) | 2010-12-14 | — | — | US | claimed |
| WO-2010083625-A1 | SYNTHETIC PROCESS FOR ANTICANCER DRUG FLUORAPACIN AND TRISULFIDE DERIVATIVES | ACEA BIOSCIENCES INC. (US) | 2010-07-29 | — | — | WO | claimed |
| US-20100191016-A1 | SYNTHETIC PROCESS FOR ANTICANCER DRUG FLUORAPACIN AND TRISULFIDE DERIVATEVES | ACEA BIOSCIENCES, INC. (US) | 2010-07-29 | — | — | US | claimed |
| US-7622507-B2 | Substituted organosulfur compounds and methods of using thereof | ACEA BIOSCIENCES INC. (US) | 2009-11-24 | — | — | US | claimed |
| US-20090192146-A1 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF | ACEA BIOSCIENCES, INC. (US) | 2009-07-30 | — | — | US | claimed |
| EP-1458393-B1 | SUBSTITUTED DIKETOPIPERAZINES AS OXYTOCIN ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-06-25 | — | — | EP | claimed |
| EP-1742635-A2 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF | Acea Biosciences, Inc. (US) | 2007-01-17 | — | — | EP | claimed |
| WO-2005112933-A2 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF | ACEA BIOSCIENCES INC. (US) | 2005-12-01 | — | — | WO | claimed |
| US-20050261321-A1 | Substituted organosulfur compounds and methods of using thereof | ACEA Therapeutics, Inc. | 2005-11-24 | — | — | US | claimed |
| CN-113663067-B | Immune activated antibody and application thereof | 深圳市康居正医药科技有限公司 | 2025-06-17 | — | — | CN | disclosed |
| WO-2024149694-A1 | NITROGENOUS HETEROCYCLES FOR ORGANIC ELECTROLUMINESCENT DEVICES | MERCK PATENT GMBH (DE) | 2024-07-18 | — | — | WO | disclosed |
| CN-220209012-U | Battery pole piece and winding battery | 微宏动力系统（湖州）有限公司 | 2023-12-19 | — | — | CN | disclosed |
| EP-0391411-A2 | 3'-Substituted methyl nucleosides as antiviral agents | Bristol-Myers Squibb Company (US) | 1990-10-10 | — | — | EP | disclosed |
| EP-0177808-A1 | 4-Methyl-5-thioformamidinomethylimidazole dihydrochloride | MECT CORPORATION (JP) | 1986-04-16 | — | — | EP | disclosed |
| EP-0177808-A1 | 4-Methyl-5-thioformamidinomethylimidazole dihydrochloride | MECT CORPORATION (JP) | 1986-04-16 | — | — | EP | disclosed |
| US-4188397-A | ANTIARTHRITIC, ANTIINFLAMMATORY | SMITHKLINE CORPORATION (US) | 1980-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192146-A1 | SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF | TST, CTH, CBS | TXN 11/4885TXNRD1 15/4885ALDH1A1 285/4885 |
| US-20100191016-A1 | SYNTHETIC PROCESS FOR ANTICANCER DRUG FLUORAPACIN AND TRISULFIDE DERIVATEVES | PFAS, PARP1, PARP2 | TXN 1587/4885TXNRD1 1497/4885ALDH1A1 3023/4885 |
| US-20050261321-A1 | Substituted organosulfur compounds and methods of using thereof | TST, CTH, CBS | TXN 11/4885TXNRD1 15/4885ALDH1A1 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.